... requires medication abortion providers, such as Plaintiffs, to comply with the regimen described on the final printed labeling (“FPL”) of the Mifeprex medication, which is used in medication abortions. Until recently, Plaintiffs used a medication abortion regimen that differed from, and was significantly safer and more effective than, the regimen required by the [legislature's] FPL mandate. However, on March 29, the Food and Drug Administration (“FDA”) updated the FPL of the Mifeprex medication to reflect the medication abortion regimen used by Plaintiffs, as well as the majority of abortion providers across the country. Therefore, Plaintiffs’ challenge to the FPL mandate has been mooted, and Plaintiffs move to amend the Complaint to drop their challenge to section 1504(a) of the Act.The filing also asked to challenge the part of the law that requires a 14-day followup check with doctors after pills are administered in the first eight weeks of pregnancy to induce a miscarriage.
Because there are medically-accepted ways to confirm termination of pregnancy, other than having a patient return approximately fourteen days later for a follow-up visit, as the new FDA FPL reflects, and because the follow-up visit requirement poses burdens for their patients, Plaintiffs seek to amend their Complaint in order to challenge the follow-up visit requirement.TheThe filing notes the state doesn't object to the dropping of the argument on the drug protocol, an indication the state recognizes it's a loser. But it will fight to protect the requirement of a followup visit.